# Myriad Genetics, Inc. (MYGN)

> Source: Nexqual · https://nexqual.com/MYGN · data as of 2026-10-23 15:50 UTC · cite as "Nexqual, Myriad Genetics, Inc. (MYGN), nexqual.com/MYGN" · informational, not investment advice.

**Price:** USD 5.81 (+0.78% today) · US market open, as of October 23, 2026 at 15:50 UTC; quotes may be delayed. Prev close 5.76 · day 5.6–5.81 · 52w 2.74–8.5 · market cap $555M · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $807M, net income -$113M (-14.0% margin) (SEC filings).
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $67K; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $28K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Hold (mean 3.22 on a 1–5 scale) (9 analysts), mean target USD 4.49 (range 2.5–8).
- Total return with dividends: 1Y -27.9% vs S&P 500 +14.7%; 5Y -81.1% vs S&P 500 +77.4%.
- Next earnings: 2026-11-04, EPS estimate USD -0.2, revenue estimate $191M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $691M | $678M | $753M | $838M | $825M | $807M |
| Gross profit | — | $476M | $517M | $585M | $577M | — |
| Operating income | -$191M | -$141M | -$257M | -$124M | -$387M | -$98.6M |
| Net income | -$27.2M | -$112M | -$263M | -$127M | -$366M | -$113M |
| EPS (diluted) | -$0.35 | -$1.39 | -$3.18 | -$1.41 | -$3.95 | — |
| Free cash flow | $600K | -$152M | — | — | — | — |
| Gross margin | — | 70.2% | 68.6% | 69.9% | 69.9% | — |
| Operating margin | -27.6% | -20.7% | -34.2% | -14.7% | -47.0% | -12.2% |
| Net margin | -3.9% | -16.5% | -35.0% | -15.2% | -44.4% | -14.0% |
| Revenue growth | +24.0% | -1.8% | +11.0% | +11.2% | -1.6% | — |
| Cash + short-term investments | $399M | $170M | $141M | $102M | — | — |
| Total debt | $0K | $0K | $38.5M | $39.6M | $120M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 0.7x · P/B 1.8x · Earnings yield -20.28%

## Insider sales (SEC Form 4, open-market, last ~7 months)
1 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-06-08 | Kumar Rashmi | Director | 15,000 | $67K | 8% | Yes | Too little history (no open-market trades in 2023 or 2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Insider purchases (SEC Form 4, open-market, last ~7 months)
1 purchase, $28K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-05-14 | Bisaro Paul | Director | 7,500 | $28K | 3.69 | Too little history (no open-market trades in 2023–2025) |

## Analysts
Consensus Hold (mean 3.22 on a 1–5 scale), 9 analysts; mean target USD 4.49 (low 2.5, high 8).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | TD Cowen | Target raised | Hold | $4 → $4.5 |
| 2026-10-02 | Craig-Hallum | Target raised | Buy | $4 → $8 |
| 2026-09-09 | UBS | Target lowered | Neutral | $6 → $3.6 |
| 2026-09-01 | Piper Sandler | Downgrade | Overweight → Underweight | $5.45 → $2 |
| 2026-08-18 | Stephens & Co. | Target lowered | Equal-Weight | $5 → $3 |
| 2026-08-03 | Wells Fargo | Target lowered | Equal-Weight | $5.5 → $3 |
| 2026-07-31 | TD Cowen | Target lowered | Hold | $6 → $4 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -27.9% | -81.1% |
| S&P 500 (SPY) | +14.7% | +77.4% |
| Per year | -27.9% | -28.4% |
| Volatility (annualized) | 95.3% | 77.4% |
| Max drawdown | -65.0% (Nov 2025→Jul 2026) | -90.7% (Oct 2021→Jul 2026) |

## Peers (Diagnostics & Research)
FLGT (Fulgent Genetics, Inc.) USD 20.06 +0.35% · CSTL (Castle Biosciences, Inc.) USD 33.07 -0.36% · OPK (Opko Health, Inc.) USD 1.62 -0.92% · FRNM (Freenome, Inc.) USD 12.61 -3.78% · PSNL (Personalis, Inc.) USD 15.82 -0.03% · WGS (GeneDx Holdings Corp.) USD 62.96 -6.23%

## More
Full page: https://nexqual.com/MYGN · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in MYGN's own 10-K filed 2026-02-24 (https://www.sec.gov/Archives/edgar/data/899923/000089992326000018/mygn-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | PATHOMIQ | "In early 2025, we entered into a strategic collaboration with PATHOMIQ, Inc. pursuant to which we obtained exclusive U.S. licensing rights to PATHOMIQ's AI-enabled diagnostic platform, PATHOMIQ_PRAD, to enhance our oncol…" |
| Partner | SOPHiA GENETICS SA (SOPH) | "In September 2025, we entered into a strategic collaboration with SOPHiA GENETICS S.A. to develop a global liquid biopsy companion diagnostic solution." |

Other companies that name MYGN in their own reports (relationship from MYGN's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | Burning Rock Biotech Ltd (BNR) | 20-F 2026-04-28 | "In addition, in November 2020, we entered into a development and commercialization agreement with Myriad Genetics, Inc. (NASDAQ: MYGN, "Myriad") to in-license Myriad myChoice® tumor testing in China." |
| partner | Profusa, Inc. (PFSA) | 10-K 2026-04-15 | "Myriad Genetics, Inc., Mayo Collaborative Services v." |
| partner | Cyngn Inc. (CYN) | 10-K 2026-03-27 | "Myriad Genetics, Inc., Mayo Collaborative Services v." |
| partner | Bionano Genomics, Inc. (BNGO) | 10-K 2026-03-23 | "Myriad Genetics, Inc., Mayo Collaborative Services v." |
| partner | Kodiak AI, Inc. (KDK) | 10-K 2026-03-11 | "Myriad Genetics, Inc., Mayo Collaborative Services v." |
| partner | ANAPTYSBIO, INC (ANAB) | 10-K 2026-03-03 | "Myriad Genetics, Inc., BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig., Mayo Collaborative Services v." |
| partner | Biohaven Ltd. (BHVN) | 10-K 2026-03-02 | "Myriad Genetics, Inc., Mayo Collaborative Services v." |
| partner | Personalis, Inc. (PSNL) | 10-K 2026-02-26 | "We are pursuing a partner-centric strategy and have key relationships with Tempus, Myriad Genetics, Inc., Moderna, and Merck, among others." |

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Cancer Care Continuum | $114.1M | 59.8% | -10.6% |
| Prenatal Health | $39.8M | 20.9% | -16.4% |
| Mental Health | $36.8M | 19.3% | -2.6% |
| Total revenue | $190.7M | 100% | — |

## Revenue by region (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| U.S. | $177.5M | 93.1% | -10.4% |
| RoW | $13.2M | 6.9% | -11.4% |
| Total revenue | $190.7M | 100% | — |

## Company outlook (8-K filed 2026-07-30)

- "Below is a table summarizing Myriad Genetics' full-year 2026 financial guidance*: (in millions, except percentages) 2026 Guidance FY 2026 Comments Revenue $770 - $790 Revised the full-year 2026 revenue range lower, reflecting Q2 results and current business trends."
- "Adjusted Gross Margin %** 66% - 67% Gross margins expected to fluctuate quarter to quarter given product mix and pricing trends. * Assumes currency rates as of July 30, 2026. ** Adjusted Gross Margin is defined as Gross Margin plus non-cash cost of sales, such as amortization of intangible assets and share-based compensation expense, and non-recurring one-time expenses."
- "As a result of second quarter 2026 performance and strategic initiatives that are underway, Myriad Genetics is suspending its previous full-year 2026 Adjusted EBITDA guidance and is providing full-year 2026 financial guidance only with respect to Revenue and Adjusted Gross Margin % as set forth above."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.20 | $0.07 | -380.6% | $191.3M | 8 |
| Next quarter (ends 2026-12-31) | $-0.18 | $0.12 | -249.3% | $196.1M | 8 |
| Current fiscal year (ends 2026-12-31) | $-0.74 | $0.05 | -1646.8% | $777.9M | 9 |
| Next fiscal year (ends 2027-12-31) | $-0.59 | $0.15 | -489.6% | $820.5M | 9 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-04): ±26.9%; last 8 reports averaged ±24.1%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 118.3% | ±26.9% |
| 2026-12-18 | 56 | 103.6% | ±33.0% |
| 2027-02-19 | 119 | 99.7% | ±42.5% |
| 2027-05-21 | 210 | 106.8% | ±62.9% |